Michael Epstein is the head of Weil’s Technology & IP Transactions practice and is based in New York. Mr. Epstein’s practice involves transactions, litigation and counseling in all areas of intellectual property. His transactional work includes structuring and negotiating technology and intellectual property acquisitions and dispositions, technology transfer and licensing arrangements, outsourcing transactions, and joint ventures and other targeted alliances. He also has extensive experience with respect to commercial transactions such as supply and sourcing agreements, distribution and other marketing agreements, and services agreements, among others. He has extensive intellectual property litigation experience as well, including handling technology-related disputes and litigations involving non-compete agreements and false advertising.
Mr. Epstein is active in community, philanthropic and public service matters. He has served on advisory panels to Congress and to the National Academy of Sciences, Institute of Medicine on intellectual property matters. He is a Trustee of the Northwell Health System, the Feinstein Institute for Medical Research, Jewish Board of Family and Children’s Services and the Jonas Salk Foundation. He is a member of the Dean’s Advisory Council, College of Arts & Sciences, Lehigh University.
Selected Transactional Experience*
- American Securities in the $1.37 billion sale of Arizona Chemical Holdings Corporation.
- Array Biopharma, Inc., in its acquisition of the oncology drugs encorafenib and binimetinib from Novartis AG, and in the resolution of a dispute with Genentech, Inc.
- Avista in its acquisition of ZEST Anchors, Inc., and in the combination of Vertical / Trigen Holdings, LLC with Osmotica Holdings Corp Limited.
- Brookfield Asset Management Inc. in its approximately $855 million acquisition of GrafTech International Ltd.
- Getty Images in intellectual property, technology and content licensing matters, including in connection with Getty Images’ acquisition of PicScout.
- Engility Holdings, Inc. in its approximately $1.3 billion stock-for-stock merger with TASC, Inc.
- G & K Services, Inc. in its $2.2 billion merger with Cintas Corporation.
- Institut Pasteur including, the dispute between Institut Pasteur and the United States Government concerning the rightful discoverer of the AIDS virus and the inventorship of the AIDS diagnostic test, and collaboration agreements between Institut Pasteur and the United States Government concerning AIDS and avian flu.
- JAB Holding Company, as leader of an investment group, in that group's $13.9 billion take-private of Keurig Green Mountain, Inc.
- The Kroger Company in its acquisitions of Roundy’s, Inc. and Vitacost.com, Inc.
- Lantheus Medical Imaging in several matters including its acquisition of products from Epix Pharmaceuticals.
- L’Oréal USA in its $1.3 billion acquisition of the CeraVe, AcneFree and AMBI skincare product brands from Valeant Pharmaceuticals International, Inc., $1.2 billion acquisition of IT Cosmetics and acquisitions of Essie Cosmetics and Urban Decay Cosmetics.
- The McGraw-Hill Companies, Inc. (n/k/a S&P Global Inc.) in the divestiture of its education business.
- Ontario Teachers’ Pension Plan in its acquisitions of APCO Holdings, PetVet Care Centers, CSC ServiceWorks Holdings. and Synergy Outdoors LLC.
- Partners Group Limited in its acquisition of a majority stake in Pacific Bells, Inc. and World Wide Wings, LLC.
- Pirelli & C. S.p.A. in most major matters involving technology and intellectual property over the past 20 years.
- Providence Equity Partners its sale of World Endurance Holdings, Inc., operator of the Ironman Triathlon competitions, to Wanda Sports Holdings (USA) Inc., and in its acquisition of an equity stake in RentPath, Inc.
- Providence Strategic Growth Partners in its investment in Burning Glass Technologies.
- Sanofi in numerous transactions, including its $25 billion exchange of Merial, its animal health business, for the consumer healthcare business of Boehringer Ingelheim GmbH, its $125 million investment in Warp Drive Bio and its acquisitions of Pluromed, Inc., Genzyme Corporation, and Chattem, Inc.
- Signet Jewelers Limited in its approximately $1.4 billion acquisition of Zale Corporation, and in its $625 million sale of convertible preferred shares to Leonard Green & Partners, the proceeds from which will be used to fund a repurchase of up to $625 million in Signet common stock.
- Snow Phipps Group in its acquisitions of Kele, Inc. and FeraDyne Outdoors, the acquisition by FeraDyne of Field Logic., Inc., and the acquisition by Cascade Environmental Holdings of TerraTherm, Inc.
- Straight Path Communications Inc. in its pending $3.1 billion sale to Verizon Communications Inc.
- Sun Life Financial Inc. in its acquisition of Prime Advisors.
- Technology Crossover Ventures in its $250 million minority investment in Vice Media.
- Thomas H. Lee Partners in its acquisitions of 1-800 CONTACTS and Systems Maintenance Services; and inVentiv Health, Inc. in THL’s sale of a 50% interest in inVentiv to Advent International, valuing inVentiv at $3.8 billion.
- TPG Growth and TPG Special Situations Partners in their acquisition of a minority stake in Spotify Technology S.A.
- VIVUS, Inc. in a licensing and supply arrangement with Metuchen Pharmaceuticals LLC.
- The Walt Disney Company on intellectual property aspects of its $4 billion acquisition of Marvel Entertainment.
Mr. Epstein is the author of the treatises, Epstein on Intellectual Property and Modern Intellectual Property, a co-author of Online – Internet Law, International Intellectual Property, and a co-editor of Drafting License Agreements, The Corporate Counsellor’s Deskbook, The Departing Employee, Doing Business in Eastern Europe, Biotechnology Law, The Trademark Law Revision Act, Joint Ventures and Other Cooperative Business Arrangements, and Trade Secrets, Restrictive Covenants and Other Safeguards. He is the author of more than sixty articles on intellectual property law as well. He has lectured all over the world on intellectual property matters, including on such topics as trade secrets, biotechnology law, computer law, e-commerce, unfair competition, outsourcing, trademark law, licensing and non-compete agreements. Mr. Epstein is a founder and co-editor of Intellectual Property & Technology Law Journal; and a member of the Editorial Boards of Computer Lawyer, Intellectual Property Strategist, and Cyberspace Lawyer.
Mr. Epstein is consistently recognized as a leading lawyer for Technology & Outsourcing in Chambers USA and has been “praised for his outstanding ability in litigation and licensing, outsourcing and strategic alliance transactions,” and as a “a seminal figure in the New York area” with “very wide-ranging and superior skills.” He is also named a leading lawyer by Legal 500 US in both Patents: Portfolio Management and Licensing and Technology: Transactions, and is recommended in Technology: Outsourcing. He is ranked as an “IP Star” for Licensing and Counseling by Managing Intellectual Property and recognized by IAM Patent 1000, where he has been noted as, “not like your typical external service provider – he acts like he’s in-house and provides extremely close support. In negotiations, he’s reasonable yet tough, and he really pushes to reach your objectives.” He is also named a “Best Lawyer” for Technology Law in New York by Best Lawyers in America and recognized for Intellectual Property by Super Lawyers.
Mr. Epstein is a member of the American Bar Association: Litigation Section; Intellectual Property Law Section; and Section on Business Law and a member of the New York State Bar Association: Intellectual Property Law Section.
Mr. Epstein is a member of the Firm’s Corporate Leadership Team and has been a member of the Firm’s Management Committee.
* Many of the acquisitions listed had separate technology/IP transactions as components of the larger transaction.